Citation

Carrión RE, Auther AM, McLaughlin D, Adelsheim S, Burton CZ, Carter CS, Niendam T, Ragland JD, Sale TG, Taylor SF, Tso IF, McFarlane WR, Cornblatt BA. Psychiatry Res. 2023; 328: e115420.

Copyright

(Copyright © 2023, Elsevier Publishing)

DOI

10.1016/j.psychres.2023.115420

PMID

37657201

Abstract

Recreational cannabis use has recently gained considerable interest as an environmental risk factor that triggers the onset of psychosis. To date, however, the evidence that cannabis is associated with negative outcomes in individuals at clinical high risk (CHR) for psychosis is inconsistent. The present study tracked cannabis usage over a 2-year period and examined its associations with clinical and neurocognitive outcomes, along with medication rates. CHR youth who continuously used cannabis had higher neurocognition and social functioning over time, and decreased medication usage, relative to non-users. Surprisingly, clinical symptoms improved over time despite the medication decreases.

Language: en

Keywords

Prevention; Cannabis; Clinical high risk for psychosis